Modufolin® is a folate-based bio-modulator designed to replace leucovorin/levoleucovorin as the preferred treatment to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-flluorouracil). It is currently being evaluated in three Phase I/II studies, two in colorectal cancer and one in osteosarcoma. Read more about Modufolin
Although several modern chemo drugs have been introduced that dramatically improve the treatment of many cancer diseases, they show limited effect in treating solid tumors. 5-FU and leucovorin/levoleucovorin is still the core treatment used today for colorectal cancer and Modufolin® has the potential to enable 5-FU to work more effectively.
Click the link below to sign up for the Isofol newsletter and stay informed about our progress.
News & Press information
Merck and Isofol enter into an exclusive supply & license agreement
Isofol Medical AB announced today that they have expanded the existing agreement and entered into a worldwide exclusive supply & license agreement with Merck KGaA and Merck & Cie (Merck) for the use of [6R]-5,10-methylenetetrahydrofolate (also known as Modufolin®) in cancer treatment.